Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Silencing Mediator for Retinoid and Thyroid hormone receptors (SMRT), also known as Nuclear Receptor Corepressor 2 (NCOR2), is a critical transcriptional coregulator that forms complexes with various nuclear receptors to mediate gene silencing [1]. In the absence of ligands or the presence of antagonists, SMRT binds to the ligand-binding domain of nuclear receptors, such as the thyroid hormone receptor (TR) and retinoic acid receptor (RAR), and recruits a corepressor complex containing histone deacetylase 3 (HDAC3) [2]. This enzymatic activity leads to the deacetylation of histones, resulting in a compact, transcriptionally inactive chromatin structure [2]. The SMRT–nuclear receptor complex plays a pivotal role in human disease, most notably in Acute Promyelocytic Leukemia (APL), where the PML-RARα fusion protein abnormally recruits SMRT to repress genes essential for myeloid differentiation [3]. Additionally, SMRT levels and its interaction with the estrogen receptor are key determinants of the therapeutic response and resistance to tamoxifen in breast cancer patients [4]. Because of its central role in epigenetic regulation and hormone signaling, the SMRT–nuclear receptor complex is a significant target for developing HDAC inhibitors and selective nuclear receptor modulators [1, 2]. Sources: [1] UniProt (Q9Y6Q9); [2] Privalsky, M. L. (2004) Annu Rev Physiol; [3] Lin, R. J., et al. (1998) Nature; [4] Girault, I., et al. (2003) Clinical Cancer Research.
Recruitment of histone deacetylase 3 (HDAC3) and other chromatin-modifying enzymes to the promoter regions of target genes, leading to transcriptional silencing through histone deacetylation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Silencing mediator for retinoid and thyroid hormone receptors (SMRT) – nuclear receptor complex (SMRT–NR complex).